PatentsUSA
Moderna Reaches Landmark $2.25 Billion Settlement with Genevant and Arbutus Over LNP Patent Dispute
Global agreement resolves U.S. and international litigation on lipid nanoparticle technology used in COVID-19 vaccines, averting imminent Delaware jury trial
Moderna, Genevant Sciences, and Arbutus Biopharma have finalized a global settlement addressing patent infringement claims related to lipid nanoparticle (LNP) delivery technology integral to Moderna’s COVID-19 vaccines. The deal includes an upfront payment of $950 million and potential additional payments up to $1.3 b…